Clinical Review

Considerations on the mode of delivery for pregnant women with hepatitis C infection 

Author and Disclosure Information

 

References

For most, CD does not reduce HCV transmission

Nine of the 11 studies found that the mode of delivery did not have a statistically significant impact on the vertical transmission rate of HCV in the total study populations.14,22-29 The remaining 2 studies found that the perinatal transmission rate of HCV was lower with cesarean delivery (CD) than with vaginal delivery.20,21 When considered together, the results of these 11 studies indicate that CD does not provide a significant reduction in the HCV transmission rate in the general population.

Our review confirms the findings of others, including a systematic review by the US Preventive Services Task Force.30 That investigation also failed to demonstrate any measurable increase in risk of HCV transmission as a result of breastfeeding.

Cesarean delivery may benefit 2 groups. Careful assessment of these studies, however, suggests that 2 select groups of patients with HCV may benefit from CD:

  • mothers co-infected with HIV, and
  • mothers with high viral loads of HCV.

In both of these populations, the vertical transmission rate of HCV was significantly reduced with CD compared with vaginal delivery. Therefore, CD should be strongly considered in mothers with HCV who are co-infected with HIV and/or in mothers who have a high viral load of HCV.

CASE Our recommendation for mode of delivery

The patient in our case scenario has both HIV infection and a very high HCV viral load. We would therefore recommend a planned CD at 38 to 39 weeks' gestation, prior to the onset of labor or membrane rupture. Although HCV infection is not a contraindication to breastfeeding, the mother's HIV infection is a distinct contraindication.


Pages

Recommended Reading

Subclinical hypothyroidism and pregnancy: Public health problem or lab finding with minimal clinical significance?
MDedge ObGyn
What every ObGyn should know about Supreme Court rulings in the recent term
MDedge ObGyn
Product Update: Addyi alcohol ban lifted, fezolinetant trial, outcomes tracker, comfort gown
MDedge ObGyn
Counseling on cannabis use in pregnancy
MDedge ObGyn
Cannabis and prenatal care
MDedge ObGyn
Ask about vaping and e-cigarette use
MDedge ObGyn
Multidisciplinary care could address fertility preservation in transgender youth
MDedge ObGyn
Umbilical cord management matters less for mothers than for infants
MDedge ObGyn
Data build on cardiovascular disease risk after GDM, HDP
MDedge ObGyn
Women with obesity need not boost calories during pregnancy
MDedge ObGyn